Therapeutic interchange between angiotensin II receptor blockers in institutionalized elderly patients. Implimenting a protocol;Intercambio terapéutico de antagonistas del receptor de la angiotensina-II en pacientes ancianos institucionalizados. Aplicación de un protocolo

Farmacia Hospitalaria

Volumn 27, Issue 5, 2003, Pages 290-297

  Peris Martí, Juan Francisco ^a,b   Faus Felipe, V J ^a   De La Vega, A ^a   Martínez Romero, Ortega G ^a   Martinez Martinez M A ^c  

^a Serv Farm Sociosanit La Florida   (Spain)

^b Centro Sociosanitario La Florida   (Spain)

^c NONE

Author keywords

Angiotensin II receptor blockers; Losartan; Pharmacy and Therapeutics Committee; Therapeutic equivalents; Therapeutic interchange

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; EPROSARTAN; IRBESARTAN; KALPRESS; LOSARTAN; NAVIXEN; PARAPRES; TELMISARTAN; TEVETENS; VALS; VALSARTAN;

AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; DRUG CHOICE; HUMAN; HYPERTENSION;

AGED; ALGORITHMS; ANTIHYPERTENSIVE AGENTS; CLINICAL PROTOCOLS; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INSTITUTIONALIZATION; LOSARTAN; RECEPTORS, ANGIOTENSIN; THERAPEUTIC EQUIVALENCY;

EID: 0142011532     PISSN: 11306343     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. American Society of Hospital Pharmacists. ASHP guidelines on formulary system management. Am J Hosp Pharm 1992; 49: 648-52.
2. Joint National Committee. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.
3. American Society of Health-System Pharmacists. ASHP therapeutic position statement on optimizing treatment of hypertension. Am J Health-Syst Pharm 2000; 57: 162-73.
4. Giles TD, Sander GE. Beyond the usual strategies for blood pressure reduction: therapeutic considerations and combination therapies. J Clin hypertens 2001; 3: 346-53.
5. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-45.
6. Song JC, White M, Pharmacologic, pharmacokinetic, and therapeutic differences among Angiotensin II receptor antagonists. Pharmacotherapy 2000; 20 (2): 130-39.
7. Rodgers JE, Patterson JH. Angioensin II-receptor blockers: clinical relevance and therapeutic role. Am J Health-Syst Pharm 58: 671-83.
8. Schaefer KL, Porter JA. Angiotensin II receptor antagonists: the prototype losartan. Ann Pharmacother 1996; 30: 625-36.
9. Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy, and tolerability in the management of hypertension. Drugs 1996; 51: 820-45.
10. Csajka C, Buclin T, Brunner HR, et al. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists. Clin Pharmacokinet 1997; 32: 1-29.
11. McClellan KJ, Goa KL. Candesartan cilexetil: a review of its use in essential hypertension. Drugs 1998; 56: 847-69.
12. Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54: 299-311.
13. Gillis JC, Markham A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997; 54: 885-902.
14. Bottorff MB, Tenero DM. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations. Pharmacotherapy 1999; 19 (4 pt 2): 73S-8.
15. Morsing P, Adler G, Brandt-Eliasson U, et al. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin. Hypertension 1999; 33: 1406-13.
16. Neutel JM, Smith DHG. Dose response and antihypertensive efficacy of the AT1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15: 206-17.
17. Mazzolai L, Maillard M, Rossat J, et al. Angiotensin II receptor blockade in normotensive subjects: a direct comparison of three AT1 receptor antagonists. Hypertension 1999; 33: 850-5.
18. Dahlof B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens 1995; 8: 578-83.
19. Gradman AH, Arcuri KE, Goldberg AI, et al. A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Hypertension 1995; 25: 1345-50.
20. Byyny RL. Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring. J Hypertens 1995; 13 (Supl. 1): S29-33.
21. Pool JL, Glazer R, Chiang YT, et al. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker. J Hum Hypertens 1999; 13: 275-81.
22. Oparil S, Dyke S, Freeman H, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18: 797-810.
23. Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998; 15: 229-40.
24. Weber M. Clinical efficacy of eprosartan. Pharmacotherapy 1999; 19 (4 pt 2): 95S-101.
25. Reif M, White WB, Fagan TC, et al. Effects of candesartan cilexetil in patients with systemic hypertension. Am J Cardiol 1998; 82: 961-5.
26. Pool JL, Guthrie RM, Littlejohn TW III, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11: 462-70.
27. Reeves RA, Lin CS, Kassler-Taub K, et al. Dose-related efficacy of irbesartan for hypertension: an integrated analysis. Hypertension 1998; 31: 1311-16.
28. Colin PR, Spence JD, Williams B, Ribeiro AB, Salto I, Benedict C, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000; 13: 418-26.
29. Kassler-Taub K, Littlejohn T, Elliott W, et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998; 11: 445-53.
30. Andersson OK, Neldham S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53-9.
31. McClellan KI, Markham A. Telmisartan. Drugs 1998; 56: 1039-44.
32. White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998; 18: 588-99.
33. Byyny RL. Losartan potassium lowers blood pressure measured by ambulatory blood pressure monitoring. J Hypertens 1995; 13 (Supl. 1): S29-33.
34. Ikeda LS, Harm SC, Arcuri KE, et al. Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hipertension. Blood Press 1997; 6: 35-43.